Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions

2020 ◽  
Author(s):  
John L. Pfail ◽  
Andrew B. Katims ◽  
Parissa Alerasool ◽  
John P. Sfakianos
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Current Status ◽  
Muscle Invasive Bladder Cancer ◽  
Future Directions ◽  
Muscle Invasive

scholarly journals Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions

2020 ◽  
Vol 6 (1) ◽  
pp. 9-23
Author(s):  
Kyle B. Zuniga ◽  
Rebecca E. Graff ◽  
David B. Feiger ◽  
Maxwell V. Meng ◽  
Sima P. Porten ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Recurrence ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Future Directions ◽  
Muscle Invasive ◽  
Bladder Cancer Recurrence

Urinary biomarkers of non-muscle-invasive bladder cancer: current status and future potential

2012 ◽  
Vol 12 (6) ◽  
pp. 743-752 ◽  
Author(s):  
Daniele Calistri ◽  
Valentina Casadio ◽  
Sara Bravaccini ◽  
Wainer Zoli ◽  
Dino Amadori
Keyword(s):  
Bladder Cancer ◽  
Urinary Biomarkers ◽  
Invasive Bladder Cancer ◽  
Current Status ◽  
Muscle Invasive Bladder Cancer ◽  
Future Potential ◽  
Muscle Invasive

Multidisciplinary Management of Muscle-Invasive Bladder Cancer: Current Challenges and Future Directions

2018 ◽  
pp. 307-318 ◽  
Author(s):  
Jeanny B. Aragon-Ching ◽  
Ryan P. Werntz ◽  
Anthony L. Zietman ◽  
Gary D. Steinberg
Keyword(s):  
Bladder Cancer ◽  
Standard Treatment ◽  
Locally Advanced ◽  
Invasive Bladder Cancer ◽  
Management Options ◽  
Muscle Invasive Bladder Cancer ◽  
Bladder Preservation ◽  
Future Directions ◽  
Muscle Invasive ◽  
Treatment Alternatives

The treatment of muscle-invasive bladder cancer (MIBC) is complex and requires a multidisciplinary collaboration among surgery, radiation, and medical oncology. Although neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) and lymph node dissection has been considered the standard treatment for MIBC, many patients are unfit for surgery or cisplatin-ineligible, and considerations for bladder-preservation strategies not only are increasingly recognized as optimal treatment alternatives, but also should feature in the range of management options presented to patients at the time of diagnosis. Apart from chemotherapy, immunotherapy has also been used with success in locally advanced and metastatic bladder cancer and is moving into the MIBC space. Prospective studies addressing trends in management that span systemic, surgical, and radiation options for patients are discussed in this article.

Sign in / Sign up

Export Citation Format

Share Document